



## **AVEO Oncology to Present at Upcoming Conferences**

**CAMBRIDGE, Mass. – February 7, 2018** – AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences:

- LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 10:00 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel.
- RBC Capital Markets Healthcare Conference on Wednesday, February 21, 2018 at 10:00 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel.

A live webcast of the presentations can be accessed by visiting the investors section of the Company's website at [www.aveooncology.com](http://www.aveooncology.com). A replay of the webcast will be archived for 30 days following the presentation date.

### **About AVEO**

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma and other cancers. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and at progressing its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome). Tivozanib (FOTIVDA®) is approved by the European Commission for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland. For more information, please visit the company's website at [www.aveooncology.com](http://www.aveooncology.com).

### **Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements of AVEO that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the section titled "Risk Factors" in AVEO's most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO's views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO's views as of any date other than the date of this press release.

#### **AVEO:**

Argot Partners

David Pitts, 212-600-1902

[aveo@argotpartners.com](mailto:aveo@argotpartners.com)